Loading organizations...
Benchling has raised $417.9M across 9 funding rounds.
Key people at Benchling.
Benchling has raised $417.9M in total across 9 funding rounds.
Benchling is a San Francisco-based enterprise software company that provides a cloud-based research and development platform for the biotechnology and pharmaceutical industries. Operating as a software-as-a-service business, the company offers electronic lab notebooks, laboratory information management systems, and molecular design tools to help scientists track, collaborate on, and analyze complex experimental data. The enterprise serves over 1,000 corporate customers and more than 200,000 individual scientists globally, supported by a workforce of approximately 750 employees. Benchling has raised over $400 million in total funding from prominent lead investors such as Sequoia Capital, Thrive Capital, and Andreessen Horowitz, ultimately reaching a peak valuation of $6.1 billion. Its digital infrastructure is utilized by major life sciences organizations, including multinational pharmaceutical developers like Gilead and Sanofi. The software company was founded in 2012 by Sajith Wickramasekara and Ashu Singhal.
Key people at Benchling.
Benchling is a cloud-based software platform designed specifically for biotechnology research and development (R&D), enabling life sciences organizations to digitize and unify their lab operations and scientific data. Its core product, the R&D Cloud, integrates electronic lab notebooks, biological sample management, workflow automation, and AI-powered tools to accelerate discovery and streamline collaboration across biotech startups, pharmaceutical companies, and academic labs. By replacing fragmented legacy systems with a flexible, scalable platform, Benchling helps users reduce manual work, improve data integrity, and speed time-to-market for new medicines, agricultural products, and biomaterials[1][2][3].
Serving scientists, lab managers, and research IT professionals, Benchling addresses the critical need for modern software tailored to the complexity of biotech R&D. Its platform supports a broad range of applications from early discovery to process development, making it a backbone for both startups and large enterprises. Benchling’s growth momentum is strong, with adoption by leading global biopharma firms and a significant presence in biotech startups, including one in four recent biotech IPOs built on its platform[1][4].
Benchling was founded over a decade ago by scientists at MIT who recognized that existing tools were inadequate for the complexity and speed of modern biological research. The founders, with backgrounds in biology and software engineering, initially developed tools like CRISPR design software for academic labs. Early on, Benchling offered its platform free to academic users to gather feedback and iterate rapidly. This grassroots adoption helped the platform expand into biotech startups and large pharmaceutical companies. Key moments include broadening its product from digital notebooks to comprehensive R&D management and bioinformatics, enabling it to serve diverse fields such as RNA therapeutics and industrial biotech[4][6].
Benchling rides the wave of digital transformation in biotechnology, where the complexity and volume of biological data demand modern, cloud-based software solutions. The timing is critical as biotech innovation accelerates in areas like gene editing, cell therapy, and synthetic biology, requiring scalable platforms that enable collaboration and data-driven decision-making. Market forces such as increasing R&D costs, regulatory demands for data integrity, and the rise of AI in science favor Benchling’s integrated approach. By enabling biotech companies to operate more efficiently and collaboratively, Benchling influences the broader ecosystem by lowering barriers to entry and fostering innovation akin to how cloud computing transformed software development[2][4][6].
Benchling is positioned to deepen its impact by expanding AI capabilities, enhancing integrations, and supporting downstream stages of biotech development beyond R&D. Trends such as personalized medicine, synthetic biology, and automation in labs will shape its evolution. As biotech continues to grow as a critical industry for health, sustainability, and materials, Benchling’s platform could become the essential infrastructure for scientific innovation worldwide. Its vision to enable running a biotech company entirely from a laptop highlights its potential to democratize access to advanced biotech tools and accelerate the pace of discovery[2][5][6].
In essence, Benchling is unlocking the power of biotechnology by bringing modern software to modern science, fueling the biotech revolution of tomorrow.
Benchling has raised $417.9M in total across 9 funding rounds.
Benchling's investors include Franklin Templeton Investments, Altimeter Capital, Adeyemi Ajao, Jamison Hill, G2VP, Sequoia Capital, SJF Ventures, Lone Pine Capital, Tiger Global, A Capital, Addition, AIX Ventures.
Benchling has raised $417.9M across 9 funding rounds. Most recently, it raised $100.0M Series F in November 2021.
